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Mutations in transmembrane protease,
serine 6 (TMPRSS6), encoding matrip-
tase-2, are responsible for the familial
anemia disorder iron-refractory iron defi-
ciency anemia (IRIDA). Patients with IRIDA
have inappropriately elevated levels of
the iron regulatory hormone hepcidin,
suggesting that TMPRSS6 is involved in
negatively regulating hepcidin expres-
sion. Hepcidin is positively regulated by
iron via the bone morphogenetic protein
(BMP)-SMAD signaling pathway. In this
study, we investigated whether BMP6 and
iron also regulate TMPRSS6 expression.
Here we demonstrate that, in vitro, treat-
ment with BMP6 stimulates TMPRSS6 ex-
pression at the mRNA and protein levels
and leads to an increase in matriptase-2
activity. Moreover, we identify that inhibi-
tor of DNA binding 1 is the key element of
the BMP-SMAD pathway to regulate TM-
PRSS6 expression in response to BMP6
treatment. Finally, we show that, in mice,
Tmprss6 mRNA expression is stimulated
by chronic iron treatment or BMP6 injec-
tion and is blocked by injection of neutral-
izing antibody against BMP6. Our results
indicate that BMP6 and iron not only
induce hepcidin expression but also in-
duce TMPRSS6, a negative regulator of
hepcidin expression. Modulation of TM-
PRSS6 expression could serve as a nega-
tive feedback inhibitor to avoid excessive
hepcidin increases by iron to help main-
tain tight homeostatic balance of sys-
temic iron levels. (Blood. 2011;118(3):
747-756)
Introduction
Transmembrane protease, serine 6 (TMPRSS6), encoding matrip-
tase-2 (MTP-2), a transmembrane serine protease produced by
the liver,1,2 was recently identified as a critical gene for iron
homeostasis.3,4 In both humans and mice, mutations in the
TMPRSS6 gene lead to a strong increase in hepcidin expression,
resulting in a dramatic decrease in ferroportin expression, and
severe iron deficiency anemia that is unresponsive to oral iron
treatment but partially responsive to parenteral iron therapy
(IRIDA).3-6 Moreover, genome-wide association studies identi-
fied common TMPRSS6 variants associated with hematologic
parameters7-9 and serum iron concentration,8,10 highlighting that
TMPRSS6 is important in the control of iron homeostasis and
normal erythropoiesis. It was recently proposed that the mecha-
nism by which TMPRSS6 inhibits hepcidin expression is by
down-regulation of the bone morphogenetic protein (BMP)–
SMAD signaling pathway via proteolytic cleavage of the BMP
coreceptor hemojuvelin.11,12
Hepcidin is an iron-regulated hepatic peptide hormone that
controls iron absorption at the intestinal level and iron release from
macrophages and hepatocytes. Hepcidin binds to the plasma
membrane iron exporter ferroportin and induces its endocytosis
and proteolysis, preventing release of iron into plasma.13 Iron14 and
inflammatory cytokines (eg, interleukin-6)15 stimulate hepcidin
expression, leading to reduced plasma iron levels. In contrast,
hypoxia, high erythropoietic activity, and iron deficiency inhibit
hepcidin expression.16
The role of the BMP-SMAD signaling pathway in regulating
hepcidin expression is now well established.17,18 BMP6, whose
mRNA expression is regulated by iron in vivo,19 is critical in mice
to activate this signaling cascade.20,21 BMP6 binds type I and type
II BMP receptors (BMPR-I and -II) in the presence of the BMP
coreceptor hemojuvelin, inducing the phosphorylation of BMPR-I
by BMPR-II. The activated receptor complex, in turn, phosphory-
lates a subset of SMAD proteins (SMAD-1/5/8). These receptor-
activated SMADs then form heteromeric complexes with the
common mediator SMAD4, and these translocate to the nucleus
where they regulate transcription of specific targets, such as
hepcidin.22 The importance of the BMP-SMAD signaling pathway
in regulating hepcidin expression and iron homeostasis in vivo is
supported by the severe iron overload phenotype seen in humans
and mice with mutations of genes in this pathway. For example,
mutation or loss of the hemojuvelin23-25 gene (HFE2, also known as
HJV) causes juvenile hemochromatosis with an indistinguishable
phenotype from juvenile hemochromatosis because of mutations or
loss of HAMP (encoding hepcidin)26,27 itself in both human patients
and in mice. Global knockout of Bmp620,21 or liver-specific
conditional knockout of Smad428 also results in a similar iron
overload phenotype in mice.
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The mechanisms by which TMPRSS6 expression is regulated
are not fully understood. Previously, it has been shown that
TMPRSS6 expression can be induced by known inhibitory stimuli
of hepcidin expression. Indeed, TMPRSS6 mRNA expression has
been demonstrated to be induced by erythropoietin29 and hypoxia30
and by acute iron deprivation at the protein level.31 In this study, we
investigated whether TMPRSS6 expression is regulated in vitro
and in vivo by one of the most important activators of hepcidin
expression, BMP6. We also assessed whether the potent physi-
ologic inducer of hepcidin, iron, can modulate TMPRSS6 mRNA
levels in vivo.
Methods
Cell culture
The human hepatocarcinoma cell line Hep3B (HB-8064, ATCC) was
cultured in ATCC-formulated Eagle Minimum Essential Medium (ATCC)
supplemented with 10% fetal bovine serum (FBS; ATCC). Cell cultures
were maintained at 37°C under 5% CO2.
Treatment of Hep3B cells with BMP6, LDN-193189, and
cycloheximide
Hep3B cells (1.2  105 per well) were seeded onto 24-well plates.
Twenty-four hours later, the culture medium was exchanged to 1% FBS
medium. After 4 hours, cells were treated with recombinant human BMP6
(5, 25, and 50 ng/mL, 16 hours; R&D Systems) and then harvested for total
RNA extraction.
For LDN-193189 experiments, the small molecule BMP inhibitor
LDN-193189 (60nM) was custom synthesized as previously described32-34
and was added 30 minutes after serum starvation. Cells were then treated
with BMP6 as previously described.
For cycloheximide experiments, cells were treated with 10 g/mL of
cycloheximide (Calbiochem) 2 hours before BMP6 treatment.
Time course of BMP6 treatment on hepcidin and TMPRSS6
expression in vitro
Hep3B cells (5 104 per well) were seeded onto 24-well plates. Seven
hours later, the culture medium was exchanged to 1% FBS medium. After
16 hours, cells were treated with recombinant human BMP6 (25 ng/mL; R&D
Systems) and then harvested for total RNA extraction 1, 4, 9, 16, 24, 32, and
48 hours after treatment.
Animals
The Institutional Animal Care and Use Committee at the Massachusetts
General Hospital (MGH) approved all of the following animal protocols.
For BMP6 injection and BMP6 antibody injection experiments, C57BL/6
mice were purchased from Taconic at 7 weeks of age, then housed in the
MGH facility and maintained on a standard rodent diet (Prolab RMH 3000
diet, 380 ppm iron) for 1 week before the start of treatment.
For BMP6 experiments, 8-week-old males received an intraperitoneal
injection of BMP6 diluted in vehicle (20mM sodium acetate, 5% mannitol
solution, pH 4.0) at 750g/kg or an equal volume of vehicle alone (n 3 per
group). Mice were killed and tissues harvested for analysis at 6 and
12 hours after injection. BMP6 was produced as previously described.35
For BMP6 antibody experiments, 8-week-old males received an
intraperitoneal injection of monoclonal anti-BMP6 antibody (R&D Sys-
tems) 15 mg/kg daily for 1 week. Control mice received an equivalent
volume of phosphate-buffered saline (n 5 per group). Mice were killed
and tissues harvested for analysis 6 hours after the last injection.
For chronic iron treatment experiments, 7-week-old C57BL/6 male
mice received an iron-deficient diet (2-6 ppm iron, TD.80396, Harlan
Teklad) for 12 to 14 days before iron administration. Then, mice were fed
with a 2% carbonyl iron diet (TD.08496, Harlan Teklad). Mice were killed
and tissue harvested at time zero (baseline), 24 hours, 48 hours, 72 hours,
1 week, or 2 weeks of iron enriched diet (n 6 per group), as previously
described.36
RNA extraction and quantitative real-time PCR
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN), with DNase I
digestion by the RNase-Free DNase Set (QIAGEN) according to the
manufacturer’s instructions. Real-time quantification of mRNA transcripts
was performed using 2-step reverse-transcribed polymerase chain reaction
(RT-PCR) using the ABI Prism 7900HT Sequence Detection System.
First-strand cDNA synthesis was performed using iScript cDNA Synthesis
Kit (Bio-Rad) according to the manufacturer’s instruction. Next,
TMPRSS6, hepcidin, SMAD7, and inhibitor of DNA binding 1 (ID1)
transcripts were amplified with specific primers (supplemental Table
1, available on the Blood Web site; see the Supplemental Materials link at
the top of the online article) and detected using the Power SYBR Green
PCR master mix (Applied Biosystems) according to the manufacturer’s
instructions. In parallel, RPL19 transcripts were amplified with specific
primers (supplemental Table 1) and detected in a similar manner to serve as
an internal control. Samples were analyzed in duplicate for each experi-
ment, and results are reported as the ratio of mean values for TMPRSS6,
hepcidin, SMAD7, and ID1 to RPL19.
Western blot analysis
Hep3B cells (3 106 per plate) were seeded in 10-cm dishes. During
seeding, cells were reverse transfected with 20 L of the liposomal
transfection reagent lipofectamine 2000 (Invitrogen) and 5nM of control
(ON-TARGET plus Nontargeting pool D-001810–10-05, Dharmacon) or
siRNA TMPRSS6 (siGENOME SMART pool siRNA D-006052, Dharma-
con) or 8 g of human TMPRSS6-FLAG cDNA.37 Five hours later, culture
medium was exchanged to stop the transfection. Twenty-four hours after
seeding, cells were treated with BMP6 (25 ng/mL; R&D Systems) and then
harvested for protein extraction 48 hours after treatment. Membrane
proteins were extracted using proteoJET Membrane Protein Extraction Kit
(Fermentas) according to the manufacturer’s instructions. Membrane
proteins were concentrated using a 3-kDa molecular weight cutoff ultrafil-
tration system (Amicon Ultra, Millipore). Proteins were quantified by using
the BCA Protein Assay (Pierce); equal amounts of membrane protein
(3.6 g) were subjected to NuPAGE Novex 6% Tris-Glycine Gel (Invitro-
gen) and then transferred to Immun-Blot PVDF Membrane (Bio-Rad).
Blots were blocked with stringent milk (10% milk, 1% bovine serum
albumin, 1% Igepal, 0.25% Tween-20, phosphate-buffered saline 1 time)
1 hour at room temperature, incubated overnight 4°C with rabbit anti-
TMPRSS6 (1:1000; Abcam). After washing with phosphate-buffered
saline–Tween-20 0.1%, blots were incubated for 1 hour at room tempera-
ture with horseradish peroxidase–conjugated secondary anti–rabbit (Sigma-
Aldrich) diluted 1:5000 in stringent milk and developed using a chemilumi-
nescence detection kit (PerkinElmer). Membranes were then stripped with
glycine buffer (0.5M, pH 2.5) and reprobed with rabbit anti–pan-cadherin
(Abcam; 1:1000) in stringent milk for normalization.
Measurement of MTP-2 activity
Hep3B cells were treated as described in the previous paragraph for the
Western blot experiments. Twenty-four hours after treatment with BMP6
(25 ng/mL) media was replaced with Optimem media (Invitrogen) again
containing BMP6. After 24 hours, conditioned media were prepared by
centrifugation (30 minutes 4000g) using a 3-kDa molecular weight cutoff
ultrafiltration system (Amicon Ultra). Protein concentration in conditioned
media was assessed by BCA test and 15 g of protein was used for
enzymatic assay.
As previously described,38 in brief, activity was assayed in Tris/
saline buffer (50mM Tris, pH 8.0, and 150mM NaCl) at 37°C by
monitoring the release of p-nitroaniline from the chromogenic substrate
N-(tert-butoxycarbonyl)-Gln-Ala-Arg-p-nitroanilide (666M; Bachem)
at a wavelength of 405 nm for up to 20 minutes.
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siRNA experiments
Hep3B cells (1.2  105 per well) were seeded onto 24-well plates. During
seeding, cells were reverse-transfected with 1 L of lipofectamine
2000 (Invitrogen) and 10nM of control (siGENOME SMART pool siRNA
D-006052, Dharmacon) or human SMAD7 (siGENOME SMART pool
siRNA D-020068, Dharmacon) or human ID1 siRNA (siGENOME SMART
pool siRNA D-005051, Dharmacon). Five hours later, culture medium was
exchanged to stop the transfection. Twenty-four hours after seeding, cells
were serum starved with FBS 1% medium and 4 hours later treated with
BMP6 (25 ng/mL, R&D Systems) and then harvested for RNA extraction
24 hours after treatment.
Results
TMPRSS6 expression is increased by BMP6
To determine whether BMP6, a known activator of hepcidin,18 can
modulate TMPRSS6 expression levels, Hep3B cells were treated
for 16 hours with 5, 25, or 50 ng/mL of BMP6, and hepcidin and
TMPRSS6 mRNA expression were measured by quantitative
real-time PCR. These data reveal that treatment with BMP6
induces a dose-dependent increase in hepcidin expression (Figure
1A). Interestingly, TMPRSS6 mRNA expression was also stimu-
lated by BMP6 in a dose-dependent manner, by 4-fold with
5 ng/mL of BMP6, by 9-fold with 25 ng/mL, and by 20-fold with
50 ng/mL (Figure 1A). Similar increases were observed after treatment
with other BMP ligands (BMP2, 4, 7, 9, and 11, supplemental Figure 1).
Using Western blot analysis, we assessed whether BMP6
treatment also led to an increase in MTP-2 protein. To assess the
specificity of the anti–matriptase-2 antibody that we used for our
experiments, we transfected Hep3B cells with previously published
human TMPRSS6-FLAG cDNA37 as a positive control, and a pool
of 4 siRNA TMPRSS6 was used as a negative control. Transfection
of Hep3B cells with 5nM of siRNA TMPRSS6 reduces TMPRSS6
mRNA expression by 93% in nontreated cells and in cells treated
with 25 ng/mL of BMP6 compared with Hep3B cells transfected
with siRNA control (supplemental Figure 2A-B). We detected an
increase by 4.3-fold in 2 specific bands for MTP-2 protein in the
membrane protein fraction of cells treated with BMP6 (Figure 1B
lane 2; Figure 1C), but not in the soluble cytosolic protein fraction.
This pattern of MTP-2 expression is in agreement with results
previously described2,11 and indicates that MTP-2 protein produced
Figure 1. TMPRSS6 expression is induced by BMP6.
(A) Hep3B cells were treated with 5, 25, and 50 ng/mL of
human BMP6 for 16 hours and were analyzed for
hepcidin and TMPRSS6 relative to RPL19 mRNAexpres-
sion by quantitative real-time RT-PCR. The mean of 3 to
8 (depending of the dose) independent experiments is
presented. Results are reported as the mean SEM for
the fold change from mock, and significant changes
represent the comparisons with mock. (B-C) Hep3B cells
were transfected with siRNA control (5nM), siRNA TM-
PRSS6 (5nM), or TMPRSS6-FLAG (8 g), and treated
with 25 ng/mL of BMP6 for 48 hours. Cells were ana-
lyzed for matriptase-2 level relative to pan-cadherin
protein by Western blot (B) followed by chemilumines-
cence quantification (C). (B) *A shorter exposure of lane
5 to better distinguish the 2 bands. (C) The mean of 3
experiments is presented, and results are reported as
the mean  SEM. (D) A total of 15 g of protein from
conditioned media of Hep3B cells transfected with siRNA
control (5nM) and siRNA TMPRSS6 (5nM) and treated
with BMP6 (25 ng/mL) for 48 hours were incubated with
666M of N-(tert-butoxycarbonyl)-Gln-Ala-Arg-p-nitroa-
nilide.Activity of matriptase-2 was assessed by measure-
ment of the release of the dye p-nitroaniline during up to
20 minutes at a wavelength of 405 nm at 37°C using a
spectrophotometer. The resulting activities (1 U corre-
sponds to a release rate of 1 mmol of p-nitroaniline per
minute) were measured in duplicate in 3 independent
experiments. Results are reported as the mean  SEM.
(A,C-D) Significant changes are as follows: *P  .05;
**P  .01; and ***P  .005.
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during BMP6 treatment is correctly targeted to the cell membrane
and is likely differentially N-link glycosylated. The 2 bands that
were increased with BMP6 treatment were abolished by transfec-
tion of TMPRSS6 siRNA (Figure 1B, lane 4; Figure 1C), and were
induced by transfection with TMPRSS6-FLAG (Figure 1B, lane
5), confirming their specificity for MTP-2.
We next addressed whether the increase in MTP-2 protein
quantity induced by BMP6 treatment resulted in an increase in
MTP-2 activity. Under our experimental conditions, detection of
cleaved soluble HJV protein by Western blot analysis in the
conditioned media of Hep3B cells treated with BMP6 ligand was not a
sensitive assay for assessing changes in MTP-2 activity (supplemental
Figure 3). To measure MTP-2 protein activity, we determined the
hydrolysis rate of N-(tert-butoxycarbonyl)-Gln-Ala-Arg-p-nitroanilide,
a specific chromogenic substrate for trypsin-like proteases,38,39 in
conditioned media derived from Hep3B cells treated with BMP6 and
transfected with either control siRNA or TMPRSS6 siRNA. Treatment
with BMP6 induced an increase by 3.6-fold of protease activity in the
conditioned media (Figure 1D). Moreover, this increase in activity was
inhibited by TMPRSS6 siRNA transfection. Thus, the increase in
MTP-2 protein expression induced by BMP6 also leads to a
concomitant increase in MTP-2 protease activity.
We then investigated whether the induction of TMPRSS6 and
hepcidin mRNA by BMP6 were contemporaneous. Hep3B cells
were treated with 25 ng/mL of BMP6 and total RNA was extracted
after several time points between 1 and 48 hours of treatment. After
1 hour, hepcidin mRNA expression was already significantly
increased by 5-fold to reach a plateau after 16 hours of treatment
( 450-fold; Figure 2A). However, TMPRSS6 mRNA expression
became significantly increased only after 9 hours of treatment with
BMP6, after which it progressively increased until 48 hours of
treatment (Figure 2A). Because of this delay in time necessary to
stimulate TMPRSS6 mRNA expression in response to BMP6
treatment, we next analyzed whether this regulation was direct or
dependent on new protein synthesis. The presence of the protein
synthesis inhibitor cycloheximide during treatment with BMP6
significantly reduced TMPRSS6 mRNA expression by 90% (Fig-
ure 2B) compared with treatment with BMP6 alone, suggesting the
Figure 2. Regulation of TMPRSS6 mRNA expression
in response to BMP6. Hep3B cells were treated with
25 ng/mL of BMP6 for several time points between 1 and
48 hours (A), and were analyzed for hepcidin and
TMPRSS6 relative to RPL19 mRNA expression by
quantitative real-time RT-PCR. (B-C) Hep3B cells re-
ceived 10 g/mL of cycloheximide (B) or 60nM of LDN-
193189 (C) before BMP6 (25 ng/mL) treatment and
were analyzed for gene expression relative to RPL19
mRNA expression by quantitative real-time RT-PCR.
The mean of 6 (A-B) and 3 (C) independent experiments
is presented. (B-C) Results are reported as the mean 
SEM for the fold change from mock (just before adding
BMP6) and significant changes represent the compari-
sons with mock. Significant changes are as follows:
*P  .05; **P  .01; and ***P  .005.
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necessity of de novo protein synthesis to regulate TMPRSS6
mRNA expression in response to BMP6.
BMP6 induction of TMPRSS6 mRNA expression is dependent
on BMP type I receptor kinase activity and ID1
Because BMP6 is a strong inducer of the BMP-SMAD pathway,
we addressed whether an intact and functional BMP-SMAD
pathway was necessary to permit an increase of TMPRSS6 mRNA
by BMP6 treatment. Before treatment with 25 ng/mL of BMP6,
Hep3B cells were first treated with LDN-193189, a small molecule
inhibitor of the BMP-SMAD pathway that inhibits BMP type
I receptor kinase activity.40 As already demonstrated with an analog
of LDN-193189, Dorsomorphin,41 treatment with LDN-193189
alone induced a significant decrease of hepcidin mRNA compared
with mock-treated cells by 4-fold. Moreover, the presence of
LDN-193189 strongly diminished the increase of hepcidin mRNA
caused by BMP6 treatment (Figure 2C). Treatment with LDN-
193189 alone induced a trend toward a decrease in TMPRSS6
mRNA expression by 31%. Interestingly, LDN-193189 signifi-
cantly reduced the increase of TMPRSS6 mRNA expression
induced by BMP6 treatment by 83% (Figure 2C), highlighting the
necessity of a functional BMP-SMAD pathway to regulate
TMPRSS6 mRNA expression.
To explore the mechanism of regulation of the TMPRSS6
mRNA expression by BMP6, we analyzed the effect of silencing
SMAD7 and ID1. We hypothesized that SMAD7 could participate
in TMPRSS6 regulation because it was demonstrated that SMAD7
is an inhibitory SMAD protein that is induced by BMP6-SMAD
signaling in hepatocytes to antagonize TGF-/BMP signaling42-44
and to suppress steady-state hepcidin expression as well as
hepcidin induction by BMP stimulation.45 To test whether SMAD7
is involved in TMPRSS6 mRNA regulation, we transfected Hep3B
cells with a pool of siRNA directed against SMAD7 and a control
siRNA pool. Treatment of Hep3B cells with BMP6 induced an
increase in SMAD7 mRNA expression by 10-fold (Figure 3A black
bars), whereas silencing of SMAD7 with siRNA transfection in
nontreated cells or cells treated with 25 ng/mL of BMP6 leads to a
reduction of SMAD7 mRNA level by 70% (Figure 3A gray bars).
However, silencing of SMAD7 expression had no effect on
TMPRSS6 mRNA expression in nontreated condition as well in
response to BMP6 treatment (Figure 3B). This finding indicates
that SMAD7 is not a participant in TMPRSS6 regulation by BMP6.
ID1 is a target transcript that is up-regulated by the BMP-
SMAD pathway. It has been shown that, in vivo, Id1 mRNA is
up-regulated in the liver in parallel with Bmp6 mRNA, phosphory-
lated SMAD1/5/8 protein, and hepcidin mRNA by iron.19,46 ID1
proteins are negative regulators of basic-helix-loop-helix transcrip-
tion factors that can either activate47 or repress transcription.48 As
shown in Figure 3C, treatment of Hep3B cells with 25 ng/mL of
BMP6 increased ID1 mRNA expression by 10-fold. Transfection
with an siRNA pool directed against ID1 leads to a decrease in ID1
expression by 50% either in nontreated cells or in cells treated with
BMP6. Surprisingly, silencing ID1 also had a consequence on
TMPRSS6 mRNA expression (Figure 3D). In Hep3B cells treated
with BMP6, the increase of TMPRSS6 mRNA expression was
significantly reduced by 67% by silencing ID1 (Figure 3D), and in
nontreated cells, TMPRSS6 mRNA expression was reduced by
30% (nonsignificant). These results suggest that ID1 is a link
between the BMP/SMAD signaling pathway and TMPRSS6 regu-
lation in response to BMP6.
Modulation of TMPRSS6 mRNA expression in vivo by BMP6
and iron
To investigate whether TMPRSS6 mRNA expression could be
modulated by BMP6 in vivo, we injected 8-week-old C57BL/6
male mice with 750 g/kg of BMP6 or vehicle alone. Six and
twelve hours after injection, mice were killed and hepcidin and
Tmprss6 mRNA expression was measured by quantitative real-
time PCR in the liver. As previously shown,20 BMP6 injection led
to a significant increase in hepatic hepcidin mRNA by 2-fold at
6 hours after injection (Figure 4A left). However, this increase was
Figure 3. TMPRSS6 expression is controlled by ID1
in response to BMP6. Hep3B cells transfected with
10nM of siRNA control, siRNA SMAD7 (A-B), or siRNA
ID1 (C-D), and treated in the absence or presence of
25 ng/mL of BMP6 for 24 hours were analyzed for
TMPRSS6 (B,D) SMAD7 (A), and ID1 (C) mRNA expres-
sion relative to RPL19 mRNA by quantitative real-time
RT-PCR. Results are reported as the mean  SEM for
the fold change from mock, and significant changes
represent the comparisons with mock (siRNA control
alone). Significant changes are as follows: *P  .05.
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transient, and hepcidin mRNA expression returned to basal levels
at 12 hours after injection (Figure 4A left). BMP6 injection induced
a significant increase in Tmprss6 mRNA expression by 1.5-fold at
12 hours after injection, but there was no change at 6 hours after
injection (Figure 4A right). This indicates that BMP6 regulates
TMPRSS6 mRNA expression in vivo, and there is a delay between
the up-regulation of hepcidin and up-regulation of Tmprss6 mRNA
expression, similar to the delay seen in in vitro experiments (Figure 2A).
To further validate the importance of the endogenous BMP6-
SMAD pathway in the regulation of TMPRSS6 expression in vivo,
8-week-old C57BL/6 mice were injected with 15 mg/kg of neutral-
izing BMP6 antibody once a day for one week to inhibit the
BMP6-SMAD pathway. In accordance with results already pub-
lished,20 anti-BMP6 treatment reduced significantly hepcidin mRNA
levels by 39% (Figure 4B left). Anti-BMP6 treatment also caused a
significant reduction in hepatic expression of Tmprss6 mRNA by
20% (Figure 4C right), indicating that Tmprss6 mRNA expression
in vivo is regulating by the BMP-SMAD pathway.
Because chronic dietary iron loading significantly increases
hepatic Bmp6 mRNA expression in mice,19,46,49 we investigated
whether chronic dietary iron loading in mice also induces Tmprss6
mRNA expression. As previously described,36 we fed 8-week-old
C57BL/6 male mice with 2% carbonyl iron diet for 2 weeks. Under
these conditions, serum iron, transferrin saturation, and liver iron
content were all significantly increased by 24 hours and for the entire
2-week time course.36 Hepcidin mRNA expression was significantly
Figure 4. TMPRSS6 expression is up-regulated in vivo by BMP6 and chronic iron treatment. (A) Eight-week-old male C57BL/6 mice received an intraperitoneal injection
of BMP6 750 g/kg animal weight (BMP6, black bars) or vehicle alone (mock, gray bars; n  3 per group) for 6 and 12 hours. (B) Eight-week-old male C57BL/6 mice received
an intraperitoneal injection of neutralizing BMP6 antibody 15 mg/kg once a day for 1 week (n  5 per group). (C) Seven-week-old male C57BL/6 mice were killed at time zero
(baseline) or after initiation of a 2% carbonyl iron diet for 24 hours, 48 hours, 72 hours, 1 week, or 2 weeks (n  6 per group). Tissues were analyzed for hepatic hepcidin and
Tmprss6 relative to Rpl19 mRNA by quantitative real-time RT-PCR. Results are reported as the mean SEM for the fold change from mock and significant changes represent
the comparisons with mock. Significant changes are as follows: *P  .05; and ***P  .005.
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increased by 2.7-fold after 24 hours and up to 3.5-fold by 48 hours above
baseline, after which hepcidin mRNA expression plateaued at 3- to
3.5-fold above baseline for the remaining 2 weeks on the 2%
carbonyl iron diet.36 ID1 was weakly induced by 2- to 3-fold above
baseline after 24 to 72 hours, and more strongly induced to 6.7-fold
by 1 week and 10-fold by 2 weeks on the high-iron diet.36 Tmprss6
mRNA expression remained unchanged at 24, 48, and 72 hours on
the 2% carbonyl iron diet and but became significantly increased
after 1 week of iron-enriched diet, reaching a peak after 2 weeks
(1.7-fold; Figure 4C).
Discussion
Iron is an essential nutrient, but free iron can form reactive oxygen
species leading to cell damage. Thus, iron homeostasis needs to be
tightly regulated. Because there is no physiologic means to excrete
iron from the body, this regulation occurs at the level of intestinal
iron absorption, and macrophage and hepatocyte iron release by
modulation of the iron exporter ferroportin and its ligand hepcidin.
There is a complex interplay between regulatory networks that
activate hepcidin expression in response to iron14,19 and inflamma-
tion,15 and those that inhibit hepcidin expression in response to
hypoxia, anemia, and iron deficiency.16 Recently, TMPRSS6, a
gene that encodes the membrane bound serine protease protein
MTP-2 and is mainly expressed in the liver, was identified as an
important inhibitor of hepcidin expression to control iron homeosta-
sis and normal erythropoiesis.7-9 Known inhibitors of hepcidin
expression, hypoxia and erythropoietin, have been shown to induce
an up-regulation of TMPRSS6 expression.29,30 Here, we investi-
gated whether known activators of hepcidin expression, including
BMP6 and iron, could also regulate TMPRSS6 expression.
We show that TMPRSS6 mRNA expression in Hep3B cells, a
widely studied hepatocyte derived hepatoma cell line, is stimulated
by BMP6. TMPRSS6 mRNA expression could also be induced by
several other BMPs which have previously been shown to strongly
stimulate hepcidin mRNA expression,18 confirming the link be-
tween the BMP-SMAD pathway and the up-regulation of
TMPRSS6 mRNA expression. Importantly, we further show that
the up-regulation of TMPRSS6 mRNA levels induced by BMP6
was almost completely abolished by treatment with LDN-193189,
a specific inhibitor of the BMP-SMAD signaling pathway, in Hep3B
cells. These experiments indicate that the BMP signaling pathway is a
potent activator of TMPRSS6 mRNA expression in vitro.
We also demonstrate a corresponding increase in MTP-2
protein levels in Hep3B cells in response to BMP6 treatment. We
used a polyclonal anti–MTP-2 antibody that was able to recognize
human MTP-2 protein bands of approximately 110 and 116 kDa in
size. Of note, 2 protein bands of similar size, which probably
represent differentially glycosylated MTP-2 protein, have been
previously reported by several groups.2,39 The specificity of the
anti–MTP-2 antibody for these protein bands was confirmed in
studies using TMPRSS6-FLAG cDNA as a positive control and by
the silencing of TMPRSS6 using specific siRNA treatment as a
negative control. The anti–MTP-2 antibody could recognize the
2 protein bands when TMPRSS6-FLAG was overexpressed in
Hep3B cells, confirming that the anti–MTP-2 antibody could
recognize full-length human MTP-2 protein. In Hep3B cells,
silencing of TMPRSS6 with specific siRNA leads to loss of the
2 protein bands (Figure 1B, lanes 3-4), indicating that these
2 bands probably represented MTP-2 protein.
Importantly, the increase in MTP-2 protein level induced by
BMP6 results in an increase in MTP-2 activity measured in an
assay using a specific peptidic substrate.39 We were unable to detect
cleavage of soluble HJV protein by MTP-2 activity induced by
BMP6 under the conditions tested. Instead, we used a highly
sensitive MTP-2 activity assay using N-(tert-butoxycarbonyl)-
Gln-Ala-Arg-p-nitroanilide as a chromogenic substrate for trypsin-
like proteases that is also suitable for MTP-2.2,39,50 The liberation of
the dye p-nitroaniline by proteolytic cleavage leads to an increase
of absorption at 405 nm, which corresponds to the protease activity.
In transfected HEK cells, MTP-2 is autocatalytically activated, and
the active fragment is released into the conditioned media.39 The
activity of MTP-2 can then be measured in the conditioned media
using the chromogenic substrate assay. We show that treatment
with BMP6 leads to an increase in the absorbance at 405 nm in the
conditioned media of Hep3B cells. This signal could be the result
of MTP-2 or other trypsin-like protease activity. However, we
show that silencing of TMPRSS6 with siRNA leads to near-
complete abolition of this increase in the 405-nm absorbance
signal. This result indicates that increase induced by BMP6 was
indeed mostly the result of MTP-2 activity, although there could be
a participation of another trypsin-like protease that is induced. It is
more probable that the inability to completely block the increase in
the 405-nm absorbance signal could be the result of incomplete
silencing by the TMPRSS6 siRNA. Nevertheless, BMP6 treatment
clearly leads to an increased cleavage of the MTP-2 peptidic
substrate.
Interestingly, the induction of TMPRSS6 mRNA is dependent
on de novo protein synthesis because the protein translation
inhibitor cycloheximide could block the increase induced by
BMP6. Indeed, the induction of TMPRSS6 mRNA expression
requires at least 9 hours of BMP6 treatment before a significant
effect is seen. This time delay is unlike the time course of other
BMP-SMAD targets, such as hepcidin and ID1, that can rapidly
increase their expression within 1 hour of BMP-SMAD pathway
activation. With promoter analysis software, we did not identify in
the TMPRSS6 promoter any BMP responsive elements (BMP-RE)
with sequences identical to the ones previously identified in the
hepcidin,51 ID1,52 and SMAD745 promoters. Thus, it is unlikely that
the BMP-SMAD pathway directly regulates TMPRSS6 mRNA
through a BMP-RE in the TMPRSS6 promoter.
Because BMP6 treatment leads to an early induction of
downstream signaling molecules and transcription modulators,
such as SMAD7 and ID1, we tested whether SMAD7 or ID1 was
involved in the later up-regulation of TMPRSS6 mRNA. We found
that, whereas the silencing of SMAD7 had no effect on TMPRSS6
induction by BMP6, silencing of ID1 significantly and strongly
blocked the increase of TMPRSS6 mRNA expression induced by
BMP6 treatment. Thus, ID1 expression appears to be important for
the up-regulation of TMPRSS6 by BMP6. This is the first
description that ID1 has a role in up-regulating TMPRSS6, and this
could subsequently lead to an indirect inhibition of hepcidin
expression (Figure 5). ID1 does not bind to DNA directly but
instead acts to prevent the formation of transcriptional activator
complexes.47,48 The specific transcriptional activator that is impor-
tant for the regulation of TMPRSS6 by ID1 is an important
question for future study.
BMP6 is also a positive regulator of hepatic Tmprss6 mRNA
expression in vivo in mice. Injection of BMP6 into mice leads to an
increase in hepatic hepcidin mRNA expression and also leads to an
increase in Tmprss6 mRNA levels in the liver. Interestingly, the
induction in Tmprss6 mRNA levels was delayed compared with the
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timing of hepcidin mRNA induction, a result that mimics the time
delay seen in vitro in Hep3B cells. Importantly, inhibition of
endogenous BMP6 in mice by administration of an anti-BMP6
monoclonal antibody significantly decreased baseline hepatic
Tmprss6 mRNA expression. These data suggest that BMP6 is a
physiologic regulator of Tmprss6 mRNA levels in vivo.
Chronic dietary iron loading is associated with increased
hepatic Bmp6 mRNA expression and Smad1/5/8 protein phosphor-
ylation after as early as 24 hours, and hepcidin induction by chronic
dietary iron loading is inhibited by coadministration with an
anti-BMP6 antibody,36 suggesting that stimulation of the BMP6-
SMAD pathway activity is a main mechanism by which iron
stimulates hepcidin expression. Here, we show that, after one week
of an iron-enriched diet, hepatic Tmprss6 mRNA expression was
significantly up-regulated, indicating that this gene is also physio-
logically regulated in response to iron overload. Given our data
showing that BMP6 up-regulates TMPRSS6 expression both in
vitro and in vivo, we hypothesize that the mechanism by which
dietary iron loading up-regulates hepatic Tmprss6 mRNA expres-
sion is by up-regulating hepatic Bmp6 mRNA expression. The
delay between the increase in Bmp6 mRNA expression and
Tmprss6 may be the result of the indirect nature of TMRPSS6
induction by BMP6 or the necessity of a high level of BMP6
expression or an accumulation of BMP6 protein to stimulate
Tmprss6 mRNA expression.
With chronic dietary iron loading, Id1 mRNA expression also
begins to be significantly up-regulated after 24 hours but is very
strongly increased after 1 week to reach the maximal expression at
2 weeks.36 This time delay parallels the time delay seen in the
induction of Tmprss6 mRNA, reinforcing the notion that ID1 is the
main regulator of TMPRSS6 expression in response to BMP6.
Interestingly, Lakhal et al30 demonstrated that hypoxia induces
TMPRSS6 mRNA expression, and Peng et al29 showed that EPO
treatment in mice also increases TMPRSS6 mRNA expression.
These studies did not examine the role of the BMP-SMAD pathway
or present information regarding a time delay in TMPRSS6 mRNA
regulation. It would be of interest to study the involvement of
BMP6 and ID1 in TMPRSS6 regulation under conditions of
hypoxia or erythropoietic drive to determine whether ID1 regula-
tion of TMPRSS6 is a broad mechanism or is only necessary in
response to BMP6 signaling and iron loading.
The induction of TMPRSS6 expression could be an important
part of a counter-regulatory feedback mechanism necessary to
prevent overshooting of hepcidin expression in response to positive
stimuli, such as iron. Indeed, it has been shown that overexpression
of TMPRSS6 cDNA in cells could prevent BMP-mediated induc-
tion of hepcidin mRNA expression.3 In our current experiments,
this notion is supported by the observation that chronic dietary iron
loading leads to hepcidin mRNA expression that reaches a plateau
after 48 hours, and this plateau lasts for up to 2 weeks.36 During this
time period, any increase in TMPRSS6 expression could be
involved in preventing further rises in hepcidin levels, thus
maintaining the plateau in hepcidin levels. Therefore, an increase in
TMPRSS6 expression may have a similar inhibitory function on
hepcidin levels as has been postulated for SMAD7, which is also
stimulated by chronic dietary iron loading19 and BMP-SMAD
signaling pathway activity in the liver,45 and functions as a
feedback inhibitor of BMP-SMAD pathway activity to down-
regulate hepcidin expression.45 Although TMPRSS6 and SMAD7
act on hepcidin expression as feedback inhibitors, it possible that
their roles are different. SMAD7 expression, similar to hepcidin
expression, is up regulated after 24 hours under chronic iron
treatment, whereas TMPRSS6 mRNA expression is significantly
increased after only 1 week of iron-enriched treatment. These
results suggest that, in response to iron, SMAD7 may participate in
the establishment of the plateau phase of hepcidin expression after
48 hours, whereas TMPRSS6 could be involved in the maintenance
of this plateau as a secondary mechanism.
In conclusion, we demonstrate here that TMPRSS6 is regulated
by known hepcidin stimulators, such as BMP6 and iron, possibly
via ID1. This regulation of TMPRSS6 is in addition to its known
regulation in response to iron deficiency, anemia, and hypoxia.
These data indicate that TMPRSS6 may be involved in fine-tuning
hepcidin expression by limiting hepcidin induction over the
long-term (ie, over weeks) by BMP6 and iron. Understanding the
role and regulation of TMPRSS6 in hepcidin regulation may
ultimately lead to new therapeutic strategies to treat diseases where
hepcidin levels are dysregulated, such as anemia of chronic disease
or hemochromatosis.
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